FindTrial
Sign In

SCT200

BIOLOGICAL6 trials

Sponsors

Sinocelltech Ltd.

Conditions

Advanced Solid TumorsAdvanced Squamous Non-small Cell Lung CancerColorectal CancerEsophageal Squamous Cell CarcinomaHead and Neck Squamous CarcinomaHead and Neck Squamous Cell CarcinomaTriple Negative Breast Neoplasms

Phase 1

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
NCT03692520
Sinocelltech Ltd.Advanced Solid Tumors
Start: 2018-09-30End: 2020-04-30Target: 90Updated: 2018-10-02
Efficacy and Safety of SCT200 in Patients With Advanced Squamous Non-small Cell Lung Cancer
NCT03808701
Sinocelltech Ltd.Advanced Squamous Non-small Cell Lung Cancer
Start: 2019-03-31End: 2019-12-31Target: 50Updated: 2019-01-17
Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRC
NCT04229537
Sinocelltech Ltd.Colorectal Cancer, Esophageal Squamous Cell Carcinoma
Start: 2020-03-01End: 2022-12-01Target: 60Updated: 2020-01-18
SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT05552807
Sinocelltech Ltd.Head and Neck Squamous Carcinoma
Start: 2022-06-15End: 2023-09-30Target: 120Updated: 2022-09-23

Phase 2

Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer
NCT03692689
Sinocelltech Ltd.Triple Negative Breast Neoplasms
Start: 2018-07-20End: 2019-12-31Target: 30Updated: 2018-10-02
SCT200 Plus Platinum-based Chemotherapy in Head and Neck Squamous Cell Carcinoma
NCT03874741
Sinocelltech Ltd.Head and Neck Squamous Cell Carcinoma
Start: 2019-05-21End: 2021-07-01Updated: 2020-05-27

Related Papers

Anti‐PD‐1 antibody (SCT‐I10A) plus anti‐EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open‐label, phase 1b clinical trial
Cancer2025-08-15
Phase Ib study of SCT200 combined with paclitaxel or docetaxel in patients with recurrent or metastatic head and neck squamous cell carcinoma following platinum-based chemotherapy and PD-1 antibody.
2025-01-30
Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
Cancer Biology and Medicine2023-12-238 citations
Efficacy and safety of anti-EGFR monoclonal antibody (SCT200) as third-line or further treatment in advanced lung squamous cell cancer.
Journal of Clinical Oncology2021-05-20